ArticleCurrent emergency and hospital medicine reports2013
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.
Article in Current emergency and hospital medicine reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Anticoagulants for people hospitalised with COVID-19: a rapid reviewThe Cochrane database of systematic reviews · 2022Pooled it
- Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies.Reviews in medical virology · 2021Pooled it
- Prophylactic anticoagulants for people hospitalised with COVID-19.The Cochrane database of systematic reviews · 2020Pooled it
- Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.Pharmacology research & perspectives · 2020Pooled it
- Significant decrease in plasmad-dimer levels and mean platelet volume after a 3-month treatment with rosuvastatin in patients with venous thromboembolism.Clinical cardiology · 2022Trial
- Safety of Percutaneous Dilatational Tracheostomy Under Uninterrupted Therapeutic Anticoagulation.Journal of clinical medicine · 2026Article
- Galactosylated GAG from a Snail Leads to Better Clot Buster.ACS central science · 2026Article
- Anti-Thrombotic Activities of Veratramine via Inhibiting Platelet Aggregation and FIIa/FXa.Biology · 2026Article
- Binding properties of marine sulfated glycans to coagulation (co)-factors using surface plasmon resonance spectroscopy.Scientific reports · 2026Article
- An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.Pharmaceutics · 2026Review
- Characterization of anticoagulated patients in a Latin American country: indications, treatment patterns, and complications.Thrombosis journal · 2026Article
- Diagnostic Value of Serum sCD40L, CCL3, and NT-ProBNP Levels in Detection of Lower Limb Venous Thrombosis among Elderly Patients with Heart Failure.Arquivos brasileiros de cardiologia · 2026Article
- True anticoagulation safety cannot be achieved without better anticoagulants.BMJ open quality · 2025Article
- [Anticoagulation in the setting of skin surgery].Dermatologie (Heidelberg, Germany) · 2025Review
- Pharmacists' self-reported confidence in providing pharmaceutical care on anticoagulants in Saudi Arabia.Journal of public health research · 2025Article
- The Additional Value of Activated Clotting Time-Guided Heparinization During Interventions for Peripheral Arterial Disease.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2025Article
- Article
- Preparation and Biochemical and Microbial Behavior of Poly(Lactide) Composites with Polyethersulfone and Copper-Complexed Cellulose Phosphate.Materials (Basel, Switzerland) · 2025Article
- Anti-Thrombotic Activity of 3-Deoxysappanchalcone via Inhibiting Platelet Aggregation and Thrombin (FIIa)/Activated Factor X (FXa) Activity.Molecules (Basel, Switzerland) · 2025Article
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis. Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have been studied and employed extensively with direct thrombin inhibitors typically reserved for patients with complications or those requiring intervention. Novel oral anticoagulants have emerged from clinical development and are expected to replace older agents with their ease of use and more favorable pharmacodynamic profiles. Hemorrhage is the main concerning adverse event with all anticoagulants. With their ubiquitous use, it becomes important for clinicians to have a sound understanding of anticoagulant pharmacology, dosing, and toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.